SMO and neoplasm: However, frequent tumor recurrence upon drug discontinuation, coupled with often intolerable side effects of long-term SMO inhibitor use, presents a significant therapeutic challenge (Basset-Séguin et al, 2017; Bertrand et al, 2021).